Metronidazol

Metronidazol
MetronidazolMetronidazolMetronidazolMetronidazol
Antiinfectives For Systemic Use
Albania & Kosovo
No
Yes
No
SA00254
Metronidazol
0.5% - (5 g/1000 ml)
Solution for infusion
Metronidazole
Glass bottle x 100 ml
Solution for infusion - 0.5% - (5 g/1000 ml) Metronidazole, a synthetic derivative of nitroimidazole, acts against gram-positive and gram-negative an … Read more

Solution for infusion - 0.5% - (5 g/1000 ml)

Metronidazole, a synthetic derivative of nitroimidazole, acts against gram-positive and gram-negative anaerobic microorganisms (Bacteroides species, including the B.fragilis bacterial group, Clostridium species, Eubacterium species, Peptococcus species, Peptostreptococcus species and against protozoan (Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia). The mechanism of action of metronidazole is not yet clear. It is thought that metronidazole inhibits the synthesis of DNA. It has bactericidal action.

Metronidazol is used in:

  • the treatment of infections caused by anaerobic microorganisms and infections from protozoa;
  • prevention of postoperative infections caused by anaerobic bacteria, especially bacteroides and anaerobic streptococci species;
  • the treatment of septicemia, bacteremia, peritonitis, brain abscess, necrotizing pneumonia, osteomyelitis, puerperal sepsis, pelvic abscess, pelvic cellulitis and postoperative infections wounds when from them are isolated sensitive anaerobic pathogen microorganisms; urogenital trichomoniasis in females (trichomonial vaginitis) and in males; bacterial vaginosis (also known as non-specific vaginitis), or anaerobic vaginosis or Gardnerella vaginitis;
  • acute ulcerative gingivitis; leg ulcers, infected by anaerobic microorganisms;
  • acute dental infections (e.g. acute pericoronitis and acute apical infections);
  • all forms of amoebiasis (intestinal and extraintestinal disease) and those of asymptomatic cyst holders;
  • giardiasis;
  • treatment of Helicobacter pylori, in combination with other medicines.

 

Recently viewed

Avacyn

Avacyn

Film coated tablets - 400mg 

Avacyn contains the active substance moxifloxacin hyrochloride, which belongs to a group of antibiotics called fluoroquinolones. Avacyn works by killing bacteria that cause infections. It is used in patients aged 18 years and above for treating the following bacterial infections when caused by bacteria against which moxifloxacin is active.

Avacyn is used for treating the following bacterial infections, when usual antibiotics cannot be used or have not worked:

  • infection of the sinuses (acute bacterial sinusitis);
  • acute exacerbations of chronic bronchitis;
  • community acquired penumonia outside the hospital (except severe cases);
  • mild to moderate infections of the female upper genital tract (pelvic inflammatory disease), including infections of the fallopian tubes and infections of the uterus mucous membrane        

Avacyn film-coated tablets are not sufficient on their own for treating this kind of infection, therefore, another antibiotic in addition to Avacyn film-coated tablets should be prescribed by your doctor for the treatment of infections of the female upper genital tract.

Avacyn film-coated tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous moxifloxacin for the following indications:

  • complicated skin and skin structure infections;
  • community acquired pneumonia.

Avacyn tablets should not be used to initiate therapy for any type of infections of the skin and soft tissue or in severe infections of the lungs.

Cinarizine 25mg

Cinarizine

Tablets - 25 mg

Avacyn

Avacyn

Solution for infusion - 400 mg/250 ml

1_copy

Atropine

Solution for injection - (0.1%) 1 mg/1 ml

Baktrim

Baktrim

Oral suspension - (200 mg + 40 mg/5 ml)

Home About Us Products Operations News & Media Our Caring
Digital Address Overview Product Categories Manufacturing News & Events Protect our People
Get In Touch Company Profile New Products Logistics Multimedia Gallery Our Giving
  Leadership Product Development New Investments Publications Company Initiatives
  History         
  Calendar